Lymphoma-like syndrome following para-aminosalicylic acid.

Mechanisms involved in the resistance of Mycobacterium tuberculosis to para-aminosalicylic acid.

That para-aminobenzoic acid antagonizes competitively the inhibitory effect of paraaminosalicylic acid on the growth of Mycobacterium tuberculosis is well known. In a previous communication (Hedgecock, 1956) it was reported that inhibition of M. tuberculosis (strain H37Rv) by para-aminosalicylic acid was reversed noncompetitively by methionine and biotin when the concentration of the inhibitor ...

HPLC analysis of para-aminosalicylic acid and its metabolite in plasma, cerebrospinal fluid and brain tissues.

Para-aminosalicylic acid (PAS), an approved drug for treatment of tuberculosis, is a promising therapeutic agent for treatment of manganese (Mn)-induced parkinsonian syndromes. Lack of a quantifying method, however, has hindered the clinical evaluation of its efficacy and there upon new drug development. This study was aimed at developing a simple and effective method to quantify PAS and its ma...

Toleration and absorption of sodium para-aminosalicylate and para-aminosalicylic acid (neopasalate). Comparison with other forms of para-aminosalicylic acid.

Para-Aminosalicylic Acid: Pas

Comparative study of concentrations in the blood of para-aminosalicylic acid in tuberculous patients.

In the Hospital Obrero of Lima we studied patients to determine concentration of PAS in blood plasma with the administration of its different forms. Sodium PAS was administered to nine patients, pure buffered PAS to 12, and PAS-K to six. The pure PAS used was buffered parasal with aluminum glycinate and calcium carbonate (Parlam-Panray); Sodium PAS was the usual and PAS-K was also of Parlam Lab...